As we stand on the cusp of a political shift in the United States, the intersection of biotechnology, regulatory policy, and healthcare is poised for profound transformation. The echoes of past disruptions—whether through political rhetoric, policy agendas, or global crises—are familiar to those in the industry. But if history has taught us anything, it is […]
Tom Spencer